Medindia LOGIN REGISTER
Medindia
Advertisement

Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million

Friday, February 1, 2008 General News
Advertisement
XI'AN, China, Jan. 31 SkystarBio-Pharmaceutical Co., Ltd. (OTC Bulletin Board: SKBI) ("Skystar", "Company"),a leading bio-pharmaceutical company in the People's Republic of China ("PRC"),today announced that the Company is raising its guidance for 2007 revenue to$15.8 million. The Company previously announced 2007 revenue guidance to bein the range of $12 - $14 million.
Advertisement

"We are proud to announce the first year operating our new veterinarymedicine facility we exceeded our revenue target for 2007. Our success inachieving our record revenue is the result of expanding our product line with62 new drug approvals, increasing our market penetration and implementing anaggressive marketing campaign," commented Skystar's Chief Executive Officer,Mr. Weibing Lu. "We look forward to another strong year for 2008 as our newvaccine facility is expected to begin large-scale production in the secondhalf of the year."
Advertisement

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company is a China-based producer anddistributor of vaccines, microorganisms and veterinary medication to cure andprevent disease in poultry, livestock, birds and pets. The Company's productline consists of more than 100 products with over 50 additional products inthe developmental stage. Skystar has formed strategic sales distributionnetworks throughout China. The Company recently completed construction of newstate-of-the-art bio-pharmaceutical facilities covering an area of almosteight acres. The new facilities meet or exceed all Good Manufacturing Practice(GMP) Certification Standards and have received GMP Certification from theChinese government. For additional information, please visithttp://www.skystarbio-pharmaceutical.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: This press release contains certain "forward-looking statements," asdefined in the United States Private Securities Litigation Reform Act of 1995,that involve a number of risks and uncertainties. Forward-looking statementsare statements that are not historical facts. Such forward-looking statementsare based upon the current beliefs and expectations of management and aresubject to risks and uncertainties, which could cause actual results to differfrom the forward-looking statements. Such factors include, but are not limitedto the Company's ability to develop new products, market acceptance of thecompany's new products, ability to obtain the regulatory approvals orclearances that are necessary to commercialize its products, ability toprotect proprietary rights, political and economic factors in the People'sRepublic of China and other factors detailed from time to time in theCompany's filings with the United States Securities and Exchange Commissionand other regulatory authorities. The Company undertakes no obligation topublicly update or revise any forward-looking statements, whether as a resultof new information, future events or otherwise.For more information, please contact: Scott Cramer Director - U.S. Representative Skystar Bio-Pharmaceutical Co., Ltd. Tel: +1-407-645-4433 Email: [email protected] Crocker Coulson, President CCG Elite Investor Relations Email: [email protected] Leslie Richardson, Financial Writer CCG Elite Investor Relations Tel: 310-231-8600 x 122 Email: [email protected]

SOURCE Skystar Bio-Pharmaceutical Co., Ltd.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close